Journal of the Korean Academy of Child and Adolescent Psychiatry

대한소아청소년정신의학회 (Korean Academy of Child and Adolescent Psychiatry)
권호 표지
DOI QR코드

DOI QR Code

Systematic Review of Suicidal Behaviors Related to Methylphenidate and Atomoxetine in Patients With Attention Deficit Hyperactivity Disorder

  • Jae Heon Kim (Department of Urology, Soonchunhyang University Seoul Hospital, College of Medicine, Soonchunhyang University) ;
  • Suyeon Park (Department of Biostatistics, Soonchunhyang University Seoul Hospital, College of Medicine, Soonchunhyang University) ;
  • Yeon Jung Lee (Department of Psychiatry, Soonchunhyang University Seoul Hospital, College of Medicine, Soonchunhyang University)
  • 투고 : 2022.11.28
  • 심사 : 2022.12.19
  • 발행 : 2023.04.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: This study investigated the relationship between suicidal behavior and the use of methylphenidate (MPH) or atomoxetine (ATX) in patients with attention deficit hyperactivity disorder (ADHD). Methods: The Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines were used to conduct a meta-analysis. The Physiotherapy Evidence Database scale was used to score the quality of the studies. Results: Nine studies were included in this quantitative analysis. The analysis included 602864 patients with ADHD (521125 and 81739 patients were taking methylphenidate [MPH group] and atomoxetine [ATX group], respectively) and 19230 healthy controls. The overall estimates were in the order of the control, MPH, and ATX groups; however, no statistically significant between-group difference was observed in the incidence of events (p=0.553 for control vs. MPH; p=1.000 for control vs. ATX; p=1.000 for MPH vs. ATX). Conclusion: The rate of suicidal behavior was higher in the ADHD groups treated with MPH and ATX than in the control group. However, no statistically significant difference was observed between the ADHD groups treated with MPH and ATX, and the control group. Therefore, MPH and ATX did not increase suicidal behavior.

키워드

과제정보

This work was supported by the National Research Foundation of Korea (NRF) grant, the Korea government (MSIT; grant number 2020R1F1A1048211), and the Soonchunhyang University Research Fund.

참고문헌

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association;2013.
  2. Barbaresi WJ, Colligan RC, Weaver AL, Voigt RG, Killian JM, Katusic SK. Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. Pediatrics 2013;131:637-644. https://doi.org/10.1542/peds.2012-2354
  3. Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry 2014;53:34-46.e2. https://doi.org/10.1016/j.jaac.2013.09.001
  4. Getahun D, Jacobsen SJ, Fassett MJ, Chen W, Demissie K, Rhoads GG. Recent trends in childhood attention-deficit/hyperactivity disorder. JAMA Pediatr 2013;167:282-288. https://doi.org/10.1001/2013.jamapediatrics.401
  5. National Institute of Mental Health. Trends in prevalence of ADHD diagnosis among children [Internet]. Bethesda, MD: NIMH [cited 2022 Aug 18]. Available from: https://www.nimh.nih.gov/health/statistics/attention-deficit-hyperactivity-disorder-adhd.
  6. Wang LJ, Lee SY, Yuan SS, Yang CJ, Yang KC, Huang TS, et al. Prevalence rates of youths diagnosed with and medicated for ADHD in a nationwide survey in Taiwan from 2000 to 2011. Epidemiol Psychiatr Sci 2017;26:624-634. https://doi.org/10.1017/S2045796016000500
  7. Song I, Shin JY. Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011. Epidemiol Health 2016;38:e2016045.
  8. Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008;47:209-218. https://doi.org/10.1097/chi.0b013e31815d88b2
  9. Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management; Wolraich M, Brown L, Brown RT, DuPaul G, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128:1007-1022. https://doi.org/10.1542/peds.2011-2654
  10. Wooltorton E. Suicidal ideation among children taking atomoxetine (Strattera). CMAJ 2005;173:1447.
  11. Janssen-Cilag Ltd. Concerta XL 18 mg prolonged-release tablets [Internet]. Leatherhead: Datapharm Ltd. [cited 2022 Aug 18]. Available from: https://www.medicines.org.uk/emc/product/6872/smpc.
  12. Erkuran HO, Cakaloz B, Onen O, Kutlu A. Suicide attempt with high dose long acting methylphenidate ingestion: a case presentation. Klinik Psikofarmakol Bulteni 2016;26:316-318. https://doi.org/10.5455/bcp.20151223093022
  13. Eryilmaz G, Gul IG, Yorbik O, Isiten N. Long-acting methylphenidate toxicity: a case report. Klinik Psikofarmakol Bulteni 2014;24:384-386. https://doi.org/10.5455/bcp.20140709015737
  14. Murat D, Arman A. Suicidal attempt with high dose long-acting methylphenidate: a case report. Marmara Med J 2013;26:165-167.
  15. Arun P, Sahni S. Methylphenidate and suicidal ideation: report of two cases. Indian J Psychiatry 2014;56:79-81. https://doi.org/10.4103/0019-5545.124721
  16. Paxton GA, Cranswick NE. Acute suicidality after commencing atomoxetine. J Paediatr Child Health 2008;44:596-598. https://doi.org/10.1111/j.1440-1754.2008.01389.x
  17. Capuano A, Scavone C, Rafaniello C, Arcieri R, Rossi F, Panei P. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation. Expert Opin Drug Saf 2014;13 Suppl 1:S69-S78. https://doi.org/10.1517/14740338.2014.941804
  18. Ljung T, Chen Q, Lichtenstein P, Larsson H. Common etiological factors of attention-deficit/hyperactivity disorder and suicidal behavior: a population-based study in Sweden. JAMA Psychiatry 2014;71:958-964. https://doi.org/10.1001/jamapsychiatry.2014.363
  19. Hurtig T, Taanila A, Moilanen I, Nordstrom T, Ebeling H. Suicidal and self-harm behaviour associated with adolescent attention deficit hyperactivity disorder-a study in the Northern Finland Birth Cohort 1986. Nord J Psychiatry 2012;66:320-328. https://doi.org/10.3109/08039488.2011.644806
  20. Moran P, Coffey C, Romaniuk H, Olsson C, Borschmann R, Carlin JB, et al. The natural history of self-harm from adolescence to young adulthood: a population-based cohort study. Lancet 2012;379:236-243. https://doi.org/10.1016/S0140-6736(11)61141-0
  21. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011;20:17-37. https://doi.org/10.1007/s00787-010-0140-6
  22. James A, Lai FH, Dahl C. Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand 2004;110:408-415. https://doi.org/10.1111/j.1600-0447.2004.00384.x
  23. Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adolesc Psychopharmacol 2014;24:426-434. https://doi.org/10.1089/cap.2014.0005
  24. Impey M, Heun R. Completed suicide, ideation and attempt in attention deficit hyperactivity disorder. Acta Psychiatr Scand 2012;125:93-102. https://doi.org/10.1111/j.1600-0447.2011.01798.x
  25. Manor I, Gutnik I, Ben-Dor DH, Apter A, Sever J, Tyano S, et al. Possible association between attention deficit hyperactivity disorder and attempted suicide in adolescents - a pilot study. Eur Psychiatry 2010;25:146-150. https://doi.org/10.1016/j.eurpsy.2009.06.001
  26. Cho SC, Kim JW, Choi HJ, Kim BN, Shin MS, Lee JH, et al. Associations between symptoms of attention deficit hyperactivity disorder, depression, and suicide in Korean female adolescents. Depress Anxiety 2008;25:E142-E146. https://doi.org/10.1002/da.20399
  27. Pringsheim T, Steeves T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2011;4:CD007990.
  28. Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther 2005;22:498-512. https://doi.org/10.1007/BF02849870
  29. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 2nd ed. Hoboken, NJ: Wiley-Blackwell;2019.
  30. Kratochvil CJ, Vaughan BS, Stoner JA, Daughton JM, Lubberstedt BD, Murray DW, et al. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics 2011;127:e862-e868. https://doi.org/10.1542/peds.2010-0825
  31. Chen Q, Sjolander A, Runeson B, D'Onofrio BM, Lichtenstein P, Larsson H. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 2014;348:g3769.
  32. Cheng N, Rahman MM, Alatawi Y, Qian J, Peissig PL, Berg RL, et al. Mixed approach retrospective analyses of suicide and suicidal ideation for brand compared with generic central nervous system drugs. Drug Saf 2018;41:363-376. https://doi.org/10.1007/s40264-017-0624-0
  33. Linden S, Bussing R, Kubilis P, Gerhard T, Segal R, Shuster JJ, et al. Risk of suicidal events with atomoxetine compared to stimulant treatment: a cohort study. Pediatrics 2016;137:e20153199.
  34. Warrer P, Thomsen PH, Dalsgaard S, Hansen EH, Aagaard L, Wallach Kildemoes H, et al. Switch in therapy from methylphenidate to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: an analysis of patient records. J Child Adolesc Psychopharmacol 2016;26:354-361. https://doi.org/10.1089/cap.2015.0060
  35. Davies M, Coughtrie A, Layton D, Shakir SA. Use of atomoxetine and suicidal ideation in children and adolescents: results of an observational cohort study within general practice in England. Eur Psychiatry 2017;39:11-16. https://doi.org/10.1016/j.eurpsy.2016.06.005
  36. Man KKC, Coghill D, Chan EW, Lau WCY, Hollis C, Liddle E, et al. Association of risk of suicide attempts with methylphenidate treatment. JAMA Psychiatry 2017;74:1048-1055. https://doi.org/10.1001/jamapsychiatry.2017.2183
  37. Huang KL, Wei HT, Hsu JW, Bai YM, Su TP, Li CT, et al. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study. Br J Psychiatry 2018;212:234-238. https://doi.org/10.1192/bjp.2018.8
  38. Liang SH, Yang YH, Kuo TY, Liao YT, Lin TC, Lee Y, et al. Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: a Taiwan nationwide population-based cohort study. Res Dev Disabil 2018;72:96-105. https://doi.org/10.1016/j.ridd.2017.10.023
  39. King SA, Casavant MJ, Spiller HA, Hodges NL, Chounthirath T, Smith GA. Pediatric ADHD medication exposures reported to US poison control centers. Pediatrics 2018;141:e20173872.
  40. PRISMA. PRISMA statement [Internet]. Oxford: PRISMA [cited 2022 Aug 18]. Available from: http://www.prisma-statement.org/PRISMAStatement/.
  41. PEDro. PEDro scale [Internet]. Camperdown: Institute for Musculoskeletal Health [cited 2022 Aug 18]. Available from: https://pedro.org.au/english/resources/pedro-scale/.
  42. Houston K, Hawton K, Shepperd R. Suicide in young people aged 15-24: a psychological autopsy study. J Affect Disord 2001;63:159-170. https://doi.org/10.1016/S0165-0327(00)00175-0
  43. Brent DA, Perper JA, Goldstein CE, Kolko DJ, Allan MJ, Allman CJ, et al. Risk factors for adolescent suicide. A comparison of adolescent suicide victims with suicidal inpatients. Arch Gen Psychiatry 1988;45:581-588. https://doi.org/10.1001/archpsyc.1988.01800300079011
  44. Renaud J, Brent DA, Birmaher B, Chiappetta L, Bridge J. Suicide in adolescents with disruptive disorders. J Am Acad Child Adolesc Psychiatry 1999;38:846-851. https://doi.org/10.1097/00004583-199907000-00014
  45. Brent DA, Baugher M, Bridge J, Chen T, Chiappetta L. Age- and sex-related risk factors for adolescent suicide. J Am Acad Child Adolesc Psychiatry 1999;38:1497-1505. https://doi.org/10.1097/00004583-199912000-00010
  46. Willcutt EG, Pennington BF, Chhabildas NA, Friedman MC, Alexander J. Psychiatric comorbidity associated with DSM-IV ADHD in a nonreferred sample of twins. J Am Acad Child Adolesc Psychiatry 1999;38:1355-1362. https://doi.org/10.1097/00004583-199911000-00009
  47. Brent DA, Perper JA, Moritz G, Allman C, Friend A, Roth C, et al. Psychiatric risk factors for adolescent suicide: a case-control study. J Am Acad Child Adolesc Psychiatry 1993;32:521-529. https://doi.org/10.1097/00004583-199305000-00006
  48. Shaffer D, Gould MS, Fisher P, Trautman P, Moreau D, Kleinman M, et al. Psychiatric diagnosis in child and adolescent suicide. Arch Gen Psychiatry 1996;53:339-348. https://doi.org/10.1001/archpsyc.1996.01830040075012
  49. Chirita V, Untu I. Kaplan and Sadock's synopsis of psychiatry: behavioural sciences/clinical psychiatry. Bulletin Integr Psychiatry 2016;22:119-123.
  50. Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications, 5th ed. Cambridge: Cambridge University Press;2021.